Literature DB >> 10360869

The placental transfer and fetal effects of levobupivacaine, racemic bupivacaine, and ropivacaine.

A C Santos1, B Karpel, G Noble.   

Abstract

BACKGROUND: The purposes of this study were to assess the effects of levobupivacaine on uterine blood flow and fetal well-being and to compare its placental transfer with that of bupivacaine and ropivacaine.
METHODS: After a control period, pregnant ewes that were fitted with instruments for long-term monitoring were randomized to receive a two-step intravenous infusion of levobupivacaine, bupivacaine, or ropivacaine, in a blinded manner, for 1 h. Maternal and fetal hemodynamics were monitored during the study. Arterial blood samples were drawn at 30 and 60 min of infusion from the mother and fetus to determine the acid-base status (60 min only) and serum drug concentrations. The fetal brain, heart, liver, lungs, adrenal glands, and kidneys were obtained to measure tissue drug levels.
RESULTS: Maternal blood pressure, central venous and intraamniotic pressures, acid-base status and uterine blood flow were unaffected by any drug infusion. In contrast to the other two local anesthetics, the infusion of bupivacaine was associated with a small but significant decrease in the ewe's heart rate. At the end of the study, the heart rate in the bupivacaine-treated animals was significantly less than in the animals treated with the other two drugs. All fetuses were in good condition at the start of study, and none of the local anesthetics affected fetal well-being. No significant differences were found among the three drugs in the maternal serum, fetal serum, fetal tissue concentrations, and tissue:serum concentration ratios.
CONCLUSIONS: Levobupivacaine was similar to bupivacaine and ropivacaine in causing no important hemodynamic changes in the pregnant ewe and fetus. There were no significant differences in the fetal serum and tissue levels of the drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360869     DOI: 10.1097/00000542-199906000-00027

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  Effect of decreased fetal perfusion on placental clearance of volatile anesthetics in a dual perfused human placental cotyledon model.

Authors:  Ryusuke Ueki; Tsuneo Tatara; Nobutaka Kariya; Noriko Shimode; Munetaka Hirose; Chikara Tashiro
Journal:  J Anesth       Date:  2014-01-03       Impact factor: 2.078

2.  Comparison of placental transfer of local anesthetics in perfusates with different pH values in a human cotyledon model.

Authors:  Ryusuke Ueki; Tsuneo Tatara; Nobutaka Kariya; Noriko Shimode; Chikara Tashiro
Journal:  J Anesth       Date:  2009-11-18       Impact factor: 2.078

Review 3.  Levobupivacaine: a review of its pharmacology and use as a local anaesthetic.

Authors:  R H Foster; A Markham
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Progress in analgesia for labor: focus on neuraxial blocks.

Authors:  J Sudharma Ranasinghe; David J Birnbach
Journal:  Int J Womens Health       Date:  2010-08-09

Review 5.  [Levobupivacaine in obstetric analgesia and anaesthesia. Where is its place?].

Authors:  D H Bremerich; B Zwissler
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

Review 6.  Effects of obstetric analgesics and anesthetics on the neonate : a review.

Authors:  Jay E Mattingly; John D'Alessio; Jaya Ramanathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  [Levobupivacaine for parturients undergoing elective caesarean delivery. A dose-finding investigation].

Authors:  D H Bremerich; S Kuschel; N Fetsch; B Zwissler; C Byhahn; D Meininger
Journal:  Anaesthesist       Date:  2007-08       Impact factor: 1.041

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine.

Authors:  Chantal A A Heppolette; Derek Brunnen; Sohail Bampoe; Peter M Odor
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.